Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (“polymer sustained”) or PSA (“polymer sustained alignment”) type.

Abstract: A liquid crystal composition and a liquid crystal display device which includes the composition are provided. The liquid crystal composition contains a specific compound having a polymerizable group as a first component, and may contain a specific compound having a large negative dielectric anisotropy and a low minimum temperature as a second component, or a specific compound having a small viscosity or a large maximum temperature as a third component. The liquid crystal composition satisfies at least one of the following characteristics: a high maximum temperature of a nematic phase, a low minimum temperature of the nematic phase, a small viscosity, a suitable optical anisotropy, a large negative dielectric anisotropy, a large specific resistance, a high stability to ultraviolet light and a high stability to heat. Alternatively, a liquid crystal composition having a suitable balance regarding at least two of the aforementioned characteristics is also provided.

Abstract: A process is described for preparing fesoterodine fumarate comprising the salification reaction of fesoterodine with fumaric acid in an organic solvent, preferably a ketone, at a temperature not greater than 45° C. Such process allows obtaining products with high yields and purities, and in particular a product having a content of (2E)-4-[(3-(3-diisopropylamino-1-phenylpropyl)-4-(2-isobutyroyloxyphenyl)methoxy]-4-oxobut-2-enoic acid less than or equal to 0.15% by mole.

Abstract: A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.

Abstract: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.

Abstract: 4-Aralkylphenols and derivatives thereof expressed by general formulas (6) and (7) are useful for producing trisphenols.

Abstract: A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.

Abstract: The invention relates to a method for producing methacrylated benzophenones and to the uses thereof.

Abstract: The present invention provides a stabilizer containing, as a main component, a bisphenol monoester and a bisphenol-based compound, wherein the area of the bisphenol-based compound is 0.15 to 70 when the area of the bisphenol monoester is set to be 100 in a chromatograph obtained by liquid chromatography analysis of the stabilizer, a method of manufacturing the same, a thermoplastic polymer composition containing the stabilizer, as well as a stabilizer that can further improve the process stability of the thermoplastic polymer, as compared with the conventional one, by compounding the stabilizer into the thermoplastic polymer through a method of stabilizing the thermoplastic polymer using the stabilizer and a method of manufacturing the stabilizer.

Abstract: The present invention provides a granular stabilizer for a polymer which is low-dusting and thus is easy to be handled. The present invention relates to a granular stabilizer for a polymer, comprising a compound shown by the formula (1): wherein R1s and R2s each independently represents a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or a cycloalkyl group having 5 to 8 carbon atoms; R3s each independently represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms; and X represents a single bond, a sulfur atom, an oxygen atom, an alkylidene group having 1 to 8 carbon atoms or a cycloalkylidene group having 5 to 8 carbon atoms.

Abstract: A process is described for preparing fesoterodine and/or fesoterodine fumarate comprising the esterification of (R)-feso deacyl with isobutyric acid or a precursor thereof, such as an isobutyryl halide or the isobutyric acid anhydride to give fesoterodine, in a mixture of water at alkaline pH and/or at least one organic solvent. This process allows obtaining products with high yields and purities, and in particular a product having a content of (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-isobutyroyloxymethyl-phenyl isobutyrate less than 1% by mole and a content of (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol less than 0.05% by mole.

Abstract: To provide a liquid crystal composition satisfying at least one characteristic such as a high maximum temperature of a nematic phase, a low minimum temperature thereof, a small viscosity, a suitable optical anisotropy, a large negative dielectric anisotropy and specific resistance, a high stability to ultraviolet light and heat, or a liquid crystal composition having a suitable balance regarding at least two characteristics; an AM device having a short response time, a large voltage holding ratio and contrast ratio, a long service life and so forth; wherein the liquid crystal composition contains a specific compound having a polymerizable group as a first component, and may contain a specific compound having a large negative dielectric anisotropy and a low minimum temperature as a second component, or a specific compound having a small viscosity or a large maximum temperature as a third component, and a liquid crystal display device contains the composition.

Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.

Abstract: A method of producing a granular substance comprising (i) a step of melting a compound of the formula (1): (wherein, R1 and R2 represent each independently a hydrogen atom, alkyl group having 1 to 8 carbon atoms or cycloalkyl group having 5 to 8 carbon atoms, R3 represents a hydrogen atom or alkyl group having 1 to 8 carbon atoms. X represents a single bond, sulfur atom, oxygen atom, alkylidene group having 1 to 8 carbon atoms or cycloalkylidene group having 5 to 8 carbon atoms) to obtain the melted substance, and (ii) a step of dropping the melted substance obtained in the step (i) into water and recovering the granular substance.

Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are hexafluoro-honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative hexafluoro-honokiol analogs include hexafluoro-honokiol, analogs in which one or both hydroxy groups are replaced with dichloroacetate esters, and analogs with increased fluorination. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers.

Abstract: Disclosed is a photo-acid generator having high developing properties, a cationic polymerization initiator having high curing properties, and a resist composition and a cationically polymerizable composition containing the photo-acid generator and the cationic polymerization initiator, respectively. Specifically, disclosed is an aromatic sulfonium salt compound of general formula (I) and a photo-acid generator, a cationic polymerization initiator, a resist composition, and a cationically polymerizable composition containing the compound. In formula (I), R1 to R19 are each hydrogen, halogen, hydroxyl, optionally hydroxyl-substituted C1-C18 alkyl, optionally hydroxyl-substituted C1-C18 alkoxy, optionally hydroxyl-substituted C1-C18 thioalkoxy, etc.; An? is a monovalent anion; at least one of R1 to R19 is a substituent selected from the group consisting of hydroxyl, hydroxyl-substituted C1-C12 ester group, hydroxyl-substituted C1-C18 alkoxy, and hydroxyl-substituted C1-C18 thioalkoxy.

Abstract: A polymer stabilizer can be molded easily by compression-molding a compound represented by formula (1): wherein, R1 and R2 represent each independently an alkyl group having 1 to 8 carbon atoms, an aryl group having 6 to 12 carbon atoms or an aralkyl group having 7 to 18 carbon atoms; R3 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, and R4 represents a hydrogen atom or a methyl group. Further, the polymer stabilizer molding of the present invention is capable of further improving the processing stability of a thermoplastic polymer.

Abstract: A granular composition comprising an organic compound having a melting point of 30 to 100° C., and a compound represented by the formula (1): wherein R1 and R2 independently represent a hydrogen atom, a C1-8 alkyl group, or a C5-8 cycloalkyl group, R3 represents a hydrogen atom or a C1-8 alkyl group, and X represents a single bond, a sulfur atom, an oxygen atom, a C1-8 alkylidene group or a C5-8 cycloalkylidene group.

Abstract: A composition of macrocyclic oligomer with at least one (meth)acrylate polymerizable group. A method includes preparing an activated precursor of an oligomer at pseudo high-dilution conditions. A method also includes preparing an activated precursor of an oligomer by reacting the precursor with an activated coupling agent, wherein the precursor is condensable and polymerizable.

Abstract: The present disclosure relates to a process for the preparation of a compound of formula (I) wherein R is hydrogen, a formyl group, a straight, branched or cyclic C1-C6 alkylcarbonyl group or a phenylcarbonyl group, or a salt thereof, characterized by the steps of reacting a compound of formula (II) with a mixture of Grignard initiator and Mg in a solvent to form a Grignard reagent, reacting the Grignard reagent with paraformaldehyde or trioxane to obtain a compound of formula (III) and then further reacting the compound of formula (III) in a known manner to obtain a compound of formula (I) and optionally salt formation.

Abstract: A bisphenol monoester compound represented by the formula (1): (in the formula (1), Rs each represent independently a hydrogen atom or a methyl group, and R? represents an alkyl group of a carbon number of 1 to 6, or a hydrogen atom).

Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Abstract: The invention provides a process for producing a compound of formula (I), wherein Y is selected from the group consisting of CH3, CH2OH, CH2CH2OH, CH2Br and Br; comprising the steps of: (i) reacting a compound of formula (II), wherein OX represents hydroxy or O?M+, in which M+ is a cation selected from Li+, Na+ and K+, and Y is as defined above; with trans-cinnamaldehyde (III), in the presence of a secondary amine compound; then (ii) treating the product of the preceding step with acid to afford the compound of formula (I). The above process may also be used in the production of tolterodine and fesoterodine, which are useful in the treatment of overactive bladder.

Abstract: A photosensitive compound whose size is smaller than conventional polymer for photoresist, and which has well-defined (uniform) structure, and a photoresist composition including the same are disclosed. The photosensitive compound represented by the following formula. Also, the present invention provides a photoresist composition comprising 1 to 85 wt % (weight %) of the photosensitive compound; 0.05 to 15 weight parts of a photo-acid generator with respect to 100 weight parts of the photosensitive compound; and 10 to 5000 weight parts of an organic solvent. In the formula, n is 0 or 1, x is 1, 2, 3, 4 or 5, y is 2, 3, 4, 5 or 6, z is 0, 1, 2, 3 or 4, R, R? and R? are independently hydrocarbon group of 1 to 30 carbon atoms, preferably 2 to 20 carbon atoms, and R?? is a hydrogen atom or hydrocarbon group of 1 to 30 carbon atoms, preferably 2 to 20 carbon atoms.

Abstract: The invention relates to a method for producing methacrylated benzophenones and to the uses thereof.

Abstract: The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterized in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments.

Abstract: The present invention provides a process for the production of a compound of formula (I) or a salt thereof, wherein R is hydrogen, a straight, branched or cyclic C1-C6 alkyl group or an aryl group which may optionally be substituted. This process comprises: (a) reacting a compound of formula (II), with a compound of formula (III), wherein R is as defined above and X is a leaving group, in the presence of N,N-di-isopropylethylamine.

Abstract: Provided herein is an impurity of fesoterodine, fesoterodine dehydroxy impurity, 2-[(1R)-3-[bis(1-methylethy)amino]-1-phenylpropyl]-4-methylphenyl isobutyrate, and a process for preparing and isolating thereof. Provided further herein is a highly pure fesoterodine or a pharmaceutically acceptable salt thereof substantially free of fesoterodine dehydroxy impurity, process for the preparation thereof, and pharmaceutical compositions comprising highly pure fesoterodine or a pharmaceutically acceptable salt thereof substantially free of dehydroxy impurity. Provided also herein is a pharmaceutical composition comprising solid particles of pure fesoterodine fumarate substantially free of dehydroxy impurity, wherein 90 volume-percent of the particles (D90) have a size of less than about 200 microns.

Abstract: The present invention provides a bisphenol monoester-based stabilizer composition that can improve resistance to discoloration at high temperature of a thermoplastic polymer compared with a conventional one using a bisphenol monoester-based stabilizer composition including a bisphenol monoester-based compound mainly, wherein a compound represented by the following formula: is contained in an area percentage by liquid chromatography analysis of 0.1 to 3%, a thermoplastic polymer composition and a method of manufacturing the thermoplastic polymer composition, a thermoplastic polymer molded product, and a method of stabilizing a thermoplastic polymer, as well as a thermoplastic polymer composition in which resistance to discoloration at high temperature is improved by using the stabilizer composition and a method of manufacturing the thermoplastic polymer composition, a thermoplastic polymer molded product, and a method of stabilizing a thermoplastic polymer.

Abstract: The present invention relates to compounds of formula (I) below in which: —R1 and R3 represent, independently of one another, a methoxy group optionally substituted by one or more fluorine atoms, —R2 and R4 represent, independently of one another, a hydrogen atom or a methoxy group optionally substituted by one or more fluorine atoms, —A represents a ring chosen from the group comprising aryl and heteroaryl groups, said ring possibly being substituted by or fused to a heterocycle, —X represents a nitrogen atom or a CH group, and —Z1 represents a hydrogen atom or a halogen atom, preferably fluorine, and —Z2 represents a hydrogen atom, a halogen atom, preferably fluorine, a C1 to C4 alkyl group, an aryl group or a —CN, —SO2NR12R13, —SO2R9, —COOR15 or —COR15 group, and also to the pharmaceutically acceptable salts thereof, the isomers thereof and the prodrugs thereof.

Abstract: Disclosed is a process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having a low content of impurities such as tolterodine and tolterodine isobutyrate.

Abstract: Provided herein are novel solid state forms of fesoterodine intermediates, (R)-4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid and (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, and processes for their preparation thereof. The solid state intermediates are useful for preparing fesoterodine or a pharmaceutically acceptable salt thereof in high purity.

Abstract: Provided herein is a novel raantlelate sail of fesoterodine, process for the preparation, pharmaceutics!! compositions, and method of treating thereof. Provided also herein are solid state forms of fesoterodine mandelate, process for the preparation, pharmaceutical compositions, and method of treating thereof. The raandelate salt of fesoterodine is useful for preparing fesoterodine free base or a pharmaceutically acceptable salt thereof; particularly fesoterodine fumaraie, in high purity.

Abstract: A process is described for preparing fesoterodine fumarate comprising the salification reaction of fesoterodine with fumaric acid in an organic solvent, preferably a ketone, at a temperature not greater than 45° C. Such process allows obtaining products with high yields and purities, and in particular a product having a content of (2E)-4-[(3-(3-diisopropylamino-1-phenylpropyl)-4-(2-isobutyroyloxyphenyl)methoxy]-4-oxobut-2-enoic acid less than or equal to 0.15% by mole.

Abstract: The present invention provides a granular stabilizer for a polymer which is low-dusting and thus is easy to be handled. The present invention relates to a granular stabilizer for a polymer, comprising a compound shown by the formula (1): wherein R1s and R2s each independently represents a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or a cycloalkyl group having 5 to 8 carbon atoms; R3s each independently represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms; and X represents a single bond, a sulfur atom, an oxygen atom, an alkylidene group having 1 to 8 carbon atoms or a cycloalkylidene group having 5 to 8 carbon atoms.

Abstract: A stabilizer for polymers with suppressed powder scattering is demanded. An amorphous compound defined by the following formula (1): wherein R1 and R2 independently denote a hydrogen atom, an alkyl group, or a cycloalkyl group; R3 denotes a hydrogen atom or an alkyl group; X denotes a single bond, a sulfur atom, an oxygen atom, an alkylidene group with 1 to 8 carbon atoms, or a cycloalkylidene group: having an endothermic peak at 15 to 25° C. determined by differential scanning calorimetry (DSC) and a solution rate of 5 mg/sec or higher in cyclohexane at 25° C. in the following test system: in the test system for solution rate, the measurement is carried out by loading a container (capacity: 100 ml, outer diameter: 55 mm, height: 70 mm) containing 50 g of cyclohexane at 25° C. with 3 g of a test substance; rotating fan type stirring blades with 38 mm diameter at a rotation speed of 100 rpm; and measuring the time taken for the test substance to be dissolved.

Abstract: A package is made by packing a compound of the formula (1) in a bag comprising a thermoplastic resin as a main component, wherein the film thickness of the bag is preferably from 50 to 200 ?m: wherein each of R1 and R2 is independently an alkyl group having 1 to 5 carbon atom(s); R3 is a hydrogen atom or an alkyl group having 1 to 3 carbon atom(s); and R4 is a hydrogen atom or a methyl group. The compound is taken out of the bag and is then added to a thermoplastic resin which may be the same as or different from the thermoplastic resin as the main component of the bag to obtain a composition; and the composition is formed into a thermoplastic resin film. In this regard, no paper chip arises even if the bag containing the above-described compound is roughly opened with a cutter or the like, and thus, occurrence of fish eye gels in the film can be suppressed when the film is formed of the composition comprising the thermoplastic resin and the above-described compound.

Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.

Abstract: A bisphenol monoester compound represented by the formula (1): (in the formula (1), Rs each represent independently a hydrogen atom or a methyl group, and R? represents an alkyl group of a carbon number of 1 to 6, or a hydrogen atom).

Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Abstract: A method for synthesizing a pentafluorophenyl acrylate polymer includes bulk polymerizing a pentafluorophenyl acrylate monomer in the presence of a free radical initiator. The reactant mixture was subjected to an ultrasonication treatment, so that the mixing of the initiator and the monomer is enhanced; carried out the bulk polymerization at 25-99° C. for a period of time, and at 100-200° C. under a vacuum pressure for another period of time to complete the bulk polymerization, so that residue amounts of the initiator, unreacted monomer and oligomer of the monomer are reduced in the resulting reaction mixture.

Abstract: A newly discovered antineoplastic compound denominated “phenstatin” is herein described as are synthetic methods for producing phenstatin and the active prodrug thereof. Phenstatin was converted to the sodium phosphate prodrug (3d) by a dibenzylphosphite phosphorylation and subsequent hydrogenolysis sequence 3b?3c?3d. Phenstatin (3b) was found to be a potent inhibitor of tubulin polymerization and the binding of colchicine to tubulin comparable to combretastatin A-4 (1b).

Abstract: Novel quaternary ammonium compounds of the formula and any stereoisomers thereof, wherein R1, R2 and R3 independently represent C1-C6 alkyl, optionally substituted with phenyl or hydroxyl, or both, and wherein any two of R1, R2 and R3 may form a ring together with the quaternary ammonium nitrogen; R4 represents —H, —CH3, or —CO—R4-1, wherein R4-1 represents —(C1-C4 alkyl), —(C1-C4 alkoxy), or —NR4-2R4-3, wherein R4-2 and R4-3 independently represent —H or —(C1-C4 alkyl); R5, R6 and R7 independently represent —H, —OCH3, —OH, —CONH2, —SO2NH2, —F, —Cl, —Br, —I, —CF3, or —(C1-C4 alkyl), optionally substituted with one or two —OH, —(C1-C4 alkoxy), —COOH, or —CO—O—(C1-C3 alkyl); and X? represents an anion of a pharmaceutically acceptable acid, the compounds for use as medicaments, use of the compounds for the manufacture of specific medicaments, and pharmaceutical compositions comprising the compounds. The present invention also concerns a method of treatment involving administration of the compounds.

Abstract: Provided is a bis(diphenylvinyl)arene compound having a reactive functional group on phenyl group, represented by below formula (1), wherein, Ar is an arylene group and has one or more substituents; R1-R22 each independently represent a hydrogen atom, a halogen atom, cyano group, nitro group, etc., and at least one of R1-R20 is a halogen atom, etc. The arene compound has sufficient solubility in an organic solvent and excellent reactivity.

Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Abstract: The present invention seeks to provide novel tetraarylethylene compounds which are substituted on the aryl rings ortho to the ethylenic carbon atoms and processes for the preparation for such compounds. The compounds have potential use as molecular templates.

Abstract: The present invention relates to novel bisbenzophenones and the use thereof as an ultraviolet light absorber. The presently claimed compounds are particularly useful, either alone or in combination with other additives, including other ultraviolet light absorbers, antioxidants and stabilizers, in stabilizing polymers and other materials from degradation by environmental forces such as actinic radiation (ultraviolet light), oxidation, moisture, atmospheric pollutants and combinations thereof.

Abstract: Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where X, Z, X1, R1, R2, Ra and Rb are as defined in the specification.

Abstract: The present invention seeks to provide novel tetraarylethylene compounds which are substituted on the aryl rings ortho to the ethylenic carbon atoms and processes for the preparation for such compounds. The compounds have potential use as molecular templates.

Abstract: The present invention relates to resins obtained by reacting a compound of formula 1 with an aldehyde and alkoxylating, in any order: wherein X is —OH, Y is ortho-, meta- or para- to X and is a radical of formula 4, wherein R5 is a C1-C30-alkyl, C2-C30-alkenyl, C6-C18-aryl, or C7-C30-alkylaryl. The resin has a molecular mass from 250 to 100,000 and is useful in methods of breaking oil-water emulsions.